Pharmaceutical Biotechnology Pv Publication: Pdf

Ethically, the field faces scrutiny regarding CRISPR-Cas9 gene editing, pricing of life-saving biologics (e.g., insulin price hikes), and the use of animal cells in production. The 2018 case of He Jiankui, who created gene-edited babies, highlighted the global need for strict ethical oversight.

The backbone of pharmaceutical biotechnology lies in recombinant DNA (rDNA) technology. Before 1982, human insulin was extracted from pigs and cattle, leading to allergic reactions and supply issues. With rDNA, scientists inserted the human insulin gene into E. coli bacteria, turning them into microscopic factories. This breakthrough paved the way for other recombinant proteins, including human growth hormone (hGH), erythropoietin (EPO) for anemia, and clotting factors for hemophilia. pharmaceutical biotechnology pv publication pdf

Traditional pharmaceuticals are small, chemically stable, and often taken orally. Biotech drugs (biologics) are massive proteins that cannot survive stomach acid and must be injected. While small molecules diffuse throughout the body, biologics are highly specific, reducing off-target side effects. For example, statins (small molecules) lower cholesterol broadly, whereas PCSK9 inhibitors (monoclonal antibodies) target a single protein in the liver with extreme precision. Before 1982, human insulin was extracted from pigs

The COVID-19 pandemic showcased the power of mRNA biotechnology. Pfizer-BioNTech and Moderna did not inject a virus or protein; they injected mRNA instructions that told human cells to produce the spike protein, triggering immunity. This platform allows for vaccine development in under 48 hours. Future applications include mRNA cancer vaccines tailored to an individual patient’s tumor mutations, as well as in vivo CAR-T cell generation. This breakthrough paved the way for other recombinant